About ADARx

Providing hope for patients with intractable disease

THE POWER IN OUR NAME

ADAR is an acronym for Adenosine Deaminase Acting on RNA. As such, our name may make you think of RNA editing, but that’s only part of the story. The word “adar” means “wide” or “great” which aptly describes the opportunities for our RNA targeting platform. The power in our name and of our technology is the ability to identify a wide range of disease targets and choose the best RNA targeting approach to deliver transformative precision therapeutics. 

Leadership Team

Zhen Li
Zhen Li, Ph.D.

President & CEO

Dr. Li is a co-founder of ADARx and a successful executive with more than two decades of diverse experience in research and development in the pharmaceutical and biotech industries. Prior to ADARx, Dr. Li served as Senior VP at Arrowhead Pharmaceuticals where she led the discovery and non-clinical development of Arrowhead’s delivery platform and multiple product candidates that are now in clinical studies. Previously, Dr. Li was a director at Merck, leading a team dedicated to siRNA development. Dr. Li received her Ph.D. in Chemistry and Chemical Biology from Harvard University, and her B.S. from Peking University.

Christopher Claeboe, Ph.D., MBA

VICE PRESIDENT, CMC AND MANUFACTURING

Dr. Claeboe joined ADARx in January 2022 with extensive experience in CGMP drug substance and drug product manufacturing through various stages of clinical development to commercialization. He previously served as Executive Director at ChemoCentryx, Inc., in which he contributed significantly to the CMC development activities for their recently approved drug Tavneos®. Prior positions include Director at Codexis, Inc. Dr. Claeboe received a Ph.D. in Organic Chemistry from the University of Virginia. He then completed his Postdoctoral Fellowship at Indiana University. Dr. Claeboe also earned his MBA from Indiana University's Kelley School of Business.

Melissa Fisher, Ph.D., J.D.

Vice President, Intellectual Property

In May 2021, Dr. Fisher joined ADARx as our Vice President of Intellectual Property. Dr. Fisher has over 15 years of oligonucleotide industry experience. Most recently, Dr. Fisher served as an Executive Director at Ionis Pharmaceuticals, Inc. holding leadership roles as Senior Patent Counsel and Head of Early-Stage Research/Academic Contract and Alliances. Dr. Fisher received her J.D. from California Western School of Law, her Ph.D. in Biochemistry and Molecular Biology from the University of California, Riverside and is a registered patent attorney with the USPTO.

Andrew Seacat, Ph.D.

Executive Director and Head of Toxicology

Dr. Seacat joined ADARx in May 2022 as Head of Toxicology. Dr. Seacat has over 20 years of experience in nonclinical drug development, toxicology, and drug safety evaluation. Dr. Seacat was most recently Senior Director, Pharmacology and Toxicology at Zogenix where he led authoring of all non-clinical sections of an NDA. Prior positions include Vice President, Preclinical Development at Latitude Pharmaceuticals, Senior Director, Preclinical Development at La Jolla Pharmaceuticals and Principal Scientist, Toxicology and Drug Safety at Allergan Pharmaceuticals. Dr. Seacat received a Doctorate in Biochemical Molecular Toxicology and completed a Postdoctoral Fellowship at Johns Hopkins University. Dr. Seacat was also Diplomate of the American Board of Toxicology (DABT2001-2015).

Rui Zhu, Ph.D.

Vice President, Research & Development

Dr. Zhu is a founding member of ADARx and joined as our Vice president of Research and Development. Dr. Zhu is an experienced drug hunter with a proven track record in the oligonucleotide field. Prior to joining ADARx, Dr. Zhu was Program Lead at Arrowhead Pharmaceuticals, where he successfully co-led 5 siRNA discovery programs to Phase I clinical trials. Dr. Zhu completed his postdoctoral research at Yale University and received his Ph.D. in organic chemistry from Tsinghua University.

Board of Directors

Sheila
Sheila Gujrathi, M.D.

Chair of the Board

Dr. Gujrathi serves as the Chair of ADARx's Board of Directors. She also serves as a Director of Janux Therapeutics and has recently served on several other boards, including Turning Point Therapeutics (as Chair), Five Prime Therapeutics and Ambrx. Dr. Gujrathi co-founded and was the Chief Executive Officer of Gossamer Bio. Prior to Gossamer Bio, Dr. Gujrathi served as Chief Medical Officer of Receptos. Prior to Receptos, Dr. Gujrathi held senior leadership roles at Bristol-Myers Squibb (BMS) and Genentech. Earlier in her career, she was a management consultant in McKinsey & Company's healthcare practice. Dr. Gujrathi received both her M.D. and her B.S. in biomedical engineering from Northwestern University. She completed her internal medicine internship and residency at Brigham and Women's Hospital and Harvard Medical School and additional fellowship training in allergy/immunology at UCSF and Stanford.

Erez
Erez Chimovits

Partner OrbiMed Advisors

Mr. Chimovits has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed Mr. Chimovits was the CEO of NasVax (TASE:NSVX). Previously, Mr. Chimovitz spent seven years with Compugen (Nasdaq:CGEN), as President, Compugen USA Inc. and Executive V.P., Commercial Operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions including with J&J, Novartis, Teva, Abbott, Medarex and others. Mr. Chimovits earned his M.B.A., M.Sc. in Microbiology and his B.Sc. from Tel Aviv University.

Simon
Simeon George, M.D.

CEO SR One Capital

Simeon George, M.D. has served on our Board of Directors since August 2021. Dr. George joined SR One in 2007 and is CEO of the fund. He earned his M.D. and M.B.A. from the University of Pennsylvania School of Medicine / Wharton and B.A. from Johns Hopkins University. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB, acquired by Sanofi for $3.7bn), Turning Point Therapeutics (TPTX), Design Therapeutics (DSGN), Progyny (PGNY), and Nkarta Therapeutics (NKTX), which he co-founded.

carl
Carl Gordon, Ph.D., CFA

Co-Head Global Private Equity at OrbiMed Advisors

Carl L. Gordon, Ph.D., is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of several public and private companies. He received a B.A. in Chemistry from Harvard College, a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and was a Fellow at The Rockefeller University.

Judith Li
Judith J. Li

Partner Lilly Asia Ventures (LAV)

Ms. Li is a Partner at LAV, based in San Francisco, and focused on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border. Ms. Li holds board appointments at a variety of LAV’s portfolio companies. Her prior experience includes McKinsey’s New York office, hospital administration at Partners Healthcare, and co-founding an interventional nephrology medical device venture. Ms. Li holds a B.A. in Neurobiology from Harvard and M.B.A. from Harvard Business School. Ms. Li is currently splitting her time between Hong Kong, Shanghai, and the Bay Area.

Zhen Li
Zhen Li, Ph.D.

President & CEO

Dr. Li is a co-founder of ADARx and a successful executive with more than two decades of diverse experience in research and development in the pharmaceutical and biotech industries. Prior to ADARx, Dr. Li served as Senior VP at Arrowhead Pharmaceuticals where she led the discovery and non-clinical development of Arrowhead’s delivery platform and multiple product candidates that are now in clinical studies. Previously, Dr. Li was a director at Merck, leading a team dedicated to siRNA development. Dr. Li received her Ph.D. in Chemistry and Chemical Biology from Harvard University, and her B.S. from Peking University.

Yuan (Eliza) Sun

Founder, Sirona Capital

Ms. Sun is the founder of Sirona Capital, a life science-dedicated investment firm with investments in the U.S., China and Europe. She currently serves as an executive board member of Hansoh Pharmaceutical Group Company Limited (Hong Kong Stock Exchange Ticker: 3692). Ms. Sun is in charge of Hansoh’s research, business development, and capital market department. Prior to joining Hansoh, Ms. Sun worked in healthcare investment management and industry research. She has a bachelor’s degree in biomedical sciences from Trinity College, University of Cambridge.